U.S. Markets open in 6 hrs 10 mins

Esperion Therapeutics, Inc. (ESPR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.03+1.06 (+4.82%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.97
Bid22.99 x 800
Ask23.02 x 900
Day's Range21.47 - 23.24
52 Week Range21.47 - 53.73
Avg. Volume812,921
Market Cap648.433M
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-5.22
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.55
  • Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers
    Simply Wall St.

    Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers

    The latest analyst coverage could presage a bad day for Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), with the analysts...

  • Esperion to Participate in Two Upcoming Virtual Investor Conferences

    Esperion to Participate in Two Upcoming Virtual Investor Conferences

    ANN ARBOR, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May. Event:Bank of America 2021 Healthcare ConferenceDate:May 13, 2021Format:Presentation & 1:1 Investor meetingsTime:10:15 a.m. ET Event:Morgan Stanley Life After Covid Thematic Conference IIDate:May 20, 2021Format:Presentation & 1:1 Investor meetingsTime:11:15 a.m. ET Live audio webcasts of these events can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replays of the webcasts will be archived on the Company's website for 90 days following the events. ESPERION Therapeutics ESPERION is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc. ESPERION Therapeutics’ Commitment to Patients with Hyperlipidemia High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events1. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal2. ESPERION's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need. References(1) ESPERION market research on file: research project interviewing 350 physicians. ESPERION Therapeutics, Inc. Sept-Oct 2018.(2) Data on file: analysis of NHANES database. ESPERION Therapeutics, Inc. 2018. Investor Contact:Kaitlyn BroscoEsperioncorporateteam@esperion.com

  • Why Esperion Therapeutics Plummeted Nearly 22% Today
    Motley Fool

    Why Esperion Therapeutics Plummeted Nearly 22% Today

    Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).